Clinical trial NCT03109158: NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Official title: Phase I/II Clinical Trial of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Carcinoma, Squamous Cell of Head and Neck
Keywords: squamous cell carcinoma
head
neck
Lead sponsor: NanoCarrier Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-04-12
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Part 1 of this study will establish a recommended Phase II (RPII) dose for the triplet combination of NC-6004 plus 5-Fluorouracil (5-FU) and cetuximab. Part 2 will provide the efficacy signal of the triplet combination in this patient population.

Detailed description: NC-6004 is a polymeric micelle-containing cisplatin as an active moiety. The nanoparticle provides sustained release of the active moiety and utilizes the enhanced permeability and retention effect to target release of platinum to tumors. Currently available nonclinical data and enhanced pharmacokinetics suggest that NC-6004 has the potential to be more active than cisplatin, with increased tolerability.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neck not suited for local therapy
* Measurable disease, as defined by RECIST v1.1
* ECOG performance status 0-1
* Adequate bone marrow reserve
* Adequate liver and renal function
* Have a negative pregnancy test result at Screening for females of childbearing potential
* Male patients must agree to use a condom during treatment and for 90 days after dosing and must agree not to donate sperm for 90 days after dosing
* Women of childbearing potential are willing to agree to use 1 of the study-defined effective methods of birth control from the time of study entry to 6 months after the last day of treatment
* Reasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of Day 1 treatment

Exclusion Criteria:

* Nasopharyngeal carcinoma
* Prior systemic chemotherapy, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 3 months before Day 1 or more than 6 months prior to Day 1 if platinum-based
* Concomitant anticancer therapy, systemic immune therapy, or hormonal therapy as cancer therapy
* Unresolved toxicity from all radiation, adjuvant/ neoadjuvant chemotherapy, other targeted treatment including investigational treatment
* History of thrombocytopenia with complications
* Known hypersensitivity to platinum compounds
* Pregnant or breastfeeding
* Active infection (infection requiring intravenous antibiotics)
* Uncontrolled hypertension
* Malignancies other than head and neck cancer within 5 years prior to Day 1 of treatment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
* Signs or symptoms of organ failure, major chronic illnesses other than cancer, or any concomitant medical or social conditions which, in the opinion of the investigator, make it undesirable for the patient to participate in the study, or which could jeopardize compliance with the protocol
* Have experienced any of the following within the 6-month period prior to Screening: unstable angina pectoris, clinically significant coronary artery disease, cerebrovascular accident, transient ischemic attack, cardiac failure with known ejection fraction less than 40%, or cardiac arrhythmia
* Any investigational treatment within 30 days or 5 half-lives, whichever is longer, of Day 1 of treatment
* Patient is unwilling or unable to comply with study procedures, or is planning to take vacation for 7 or more consecutive days during the treatment phase of the study without prior consent from the medical monitor
* Any other medical or social condition that, in the opinion of the investigator, would not permit the patient to complete the study or sign informed consent

Primary outcomes:
measure: RPII dose for the combination of NC-6004 plus 5-FU plus cetuximab.
timeFrame: Up to day 90
measure: Progression free survival in patients following treatment with NC-6004 plus 5-FU plus cetuximab.
timeFrame: Up to day 90
Secondary outcomes:
measure: Overall response rate
timeFrame: Up to day 90
measure: EORTC QLQ-C30
timeFrame: Up to day 90
measure: QLQ-Head and Neck 35
timeFrame: Up to day 90
Other outcomes:
measure: Incidence and severity of AEs and laboratory abnormalities
timeFrame: Up to day 90
measure: Occurrence of SAEs and treatment discontinuations due to AEs
timeFrame: Up to day 90
Locations:
city: Los Angeles
country: United States
facility: Cedars Sinai Medical Center
state: California
city: Atlanta
country: United States
facility: Winship Cancer Institute, Emory University
state: Georgia
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Detroit
country: United States
facility: Barbara Ann Karmanos Cancer Center
state: Michigan
city: Billings
country: United States
facility: Intermountain Precision Genomics
state: Montana
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: Chapel Hill
country: United States
facility: University of North Carolina at Chapel Hill
state: North Carolina
city: Oklahoma City
country: United States
facility: The University of Oklahoma Health Sciences Center
state: Oklahoma
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
city: Shumen
country: Bulgaria
facility: Complex Oncology Center - Shumen EOOD
city: Sofia
country: Bulgaria
facility: Multiprofile Hospital for Active Treatment Serdika EOOD
city: Nyíregyháza
country: Hungary
facility: Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
city: Pécs
country: Hungary
facility: Pecsi Tudomanyegyetem
city: Szekszárd
country: Hungary
facility: Tolna Megyei Balassa Janos Korhaz
city: Bucharest
country: Romania
facility: Coltea Clinical Hospital
city: Cluj-Napoca
country: Romania
facility: Prof Dr I Chiricuta Institute of Oncology
city: Craiova
country: Romania
facility: Oncology Center Sfantul Nectarie
city: Iaşi
country: Romania
facility: Euroclinic Oncology Center SRL
city: Iaşi
country: Romania
facility: Institutul Regional de Oncologie Iasi
Study officials:
affiliation: NanoCarrier Co., Ltd.
name: Atsushi Osada, Study Director
role: STUDY_DIRECTOR
References: